RM

RESERVE MEDS

RESERVED FOR YOU.

PATIENT ACCESS BRIEF

Dupixent in Saudi Arabia

The SFDA named-patient coordination pathway for formulary gaps — indicative 2026

IMMUNOLOGY · TYPE-2 INFLAMMATION IL-4RA

The clinical situation

Dupixent (dupilumab) is an FDA-approved human monoclonal antibody against IL-4 receptor alpha that blocks the shared IL-4 and IL-13 signalling axis, with indications spanning atopic dermatitis, severe asthma, eosinophilic oesophagitis, prurigo nodularis, and chronic spontaneous urticaria. Developed by Regeneron and Sanofi. Dupixent is locally registered in Saudi Arabia for major indications, so this guide specifically addresses formulary-gap scenarios — an indication not on an insurer formulary, a paediatric age band not locally covered, a presentation gap, or a bridge supply while local coverage is pending. Administration is subcutaneous, with a loading dose followed by every-two-weeks or every-four-weeks maintenance depending on indication, age, and weight.

The pathway, 5 steps

1. **Consultation & clinical rationale.** Your treating dermatologist, pulmonologist, allergist, or gastroenterologist documents diagnosis, age/weight, prior therapy, and the specific formulary-gap reason local supply does not meet the need.
2. **SFDA named-patient application.** Your physician or the importing pharmacy files the formulary-gap justification, Saudi licence verification, patient reference, and dosing plan.
3. **US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under documented chain of custody.
4. **Cold-chain shipment & arrival.** Temperature-controlled transport; the importer of record receives and hands off per your physician's protocol.
5. **Initiation & re-supply cadence.** Most patients or caregivers self-inject at home after training; Reserve Meds supports the q2w / q4w maintenance cadence.

Indicative economics

Reference US cash-pay range: USD 3,500–4,000 per month at typical adult dosing (paediatric weight-banded dosing often lower; Reserve Meds issues a transparent delivered quote at intake).

Indicative first-shipment timing

10–21 days from a complete SFDA application to first shipment, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Physician documentation kit keyed to the SFDA formulary-gap review. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case**

lead. Named point of contact for family and specialist team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Dupixent × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemeds.com/access-guides/dupixent-saudi-arabia.html

SCAN TO JOIN

reservemeds.com · hello@reservemeds.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team